1. Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study
- Author
-
Nielsen, L.K., Stege, C., Lissenberg-Witte, B., Holt, B. (Bronno) van der, Mellqvist, U.H. (U. H.), Salomo, M, Bos, G. (Gert), Levin, M.-D. (Mark-David), Visser-Wisselaar, H., Hansson, M, van der Velden, A., Deenik, W. (Wendy), Coenen, J., Hinge, M., Klein, S. (Stefan), Tanis, B., Szatkowski, D., Brouwer, R.W. (Reinoud), Westerman, M. (Matthijs), Leys, R., Sinnige, H. (Harm), Haukas, E, van der Hem, K., Durian, M.F. (Marc), Gimsing, P. (Peter), van de Donk, N, Sonneveld, P. (Pieter), Waage, A. (Anders), Abildgaard, N. (Niels), Zweegman, S. (Sonja), Nielsen, L.K., Stege, C., Lissenberg-Witte, B., Holt, B. (Bronno) van der, Mellqvist, U.H. (U. H.), Salomo, M, Bos, G. (Gert), Levin, M.-D. (Mark-David), Visser-Wisselaar, H., Hansson, M, van der Velden, A., Deenik, W. (Wendy), Coenen, J., Hinge, M., Klein, S. (Stefan), Tanis, B., Szatkowski, D., Brouwer, R.W. (Reinoud), Westerman, M. (Matthijs), Leys, R., Sinnige, H. (Harm), Haukas, E, van der Hem, K., Durian, M.F. (Marc), Gimsing, P. (Peter), van de Donk, N, Sonneveld, P. (Pieter), Waage, A. (Anders), Abildgaard, N. (Niels), and Zweegman, S. (Sonja)
- Abstract
Data on the impact of long term treatment with immunomodulatory drugs (IMiD) on health-related quality of life (HRQoL) is limited. The HOVON-87/NMSG18 study was a randomized, phase 3 study in newly diagnosed transplant ineligible patients with multiple myeloma, comparing melphalan-prednisolone in combination with thalidomide or lenalidomide, followed by maintenance therapy until progression (MPT-T or MPR-R). The EORTC QLQ-C30 and MY20 questionnaires were completed at baseline, after three and nine induction cycles and six and 12 months of maintenance therapy. Linear mixed models and minimal important differences were used for evaluation. 596 patients participated in HRQoL reporting. Patients reported clinically relevant improvement in global quality of life (QoL), future perspective and role and emotional functioning, and less fatigue and pain in both arms. The latter being of large effect size.
- Published
- 2019
- Full Text
- View/download PDF